We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Cytovale

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-movin... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Rapid Microfluidic Test Demonstrates Efficacy as Diagnostic Aid to Improve Sepsis Triage in ED

By LabMedica International staff writers
Posted on 24 May 2023
Print article
Image: IntelliSep is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying ED patients with sepsis (Photo courtesy of Cytovale)
Image: IntelliSep is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying ED patients with sepsis (Photo courtesy of Cytovale)

Sepsis is the primary cause of mortality worldwide, accounting for over 350,000 fatalities annually in the United States alone, a figure that surpasses deaths from opioid overdoses, prostate cancer, and breast cancer combined. Now, newly presented data for a groundbreaking diagnostic tool further reinforce its potential to facilitate rapid and clinically actionable sepsis diagnoses in emergency departments (EDs).

Cytovale’s (San Francisco, CA, USA) IntelliSep sepsis test is an innovative diagnostic tool that assists medical professionals in swiftly detecting sepsis, enabling crucial, time-critical clinical decisions. The test generates a result, known as the IntelliSep Index (ISI), in less than 10 minutes, classifying patients into three groups based on their sepsis likelihood, with Band 1 indicating low probability and Band 3 suggesting high probability. Newly presented data from the multi-center CV-SQuISH-ED clinical validation study further emphasize IntelliSep’s precision in stratifying patients based on sepsis and death risk, underlining its potential as a practical tool for clinicians during the decision-making process.

The study, involving 572 patients, demonstrated that the IntelliSep test accurately identified three statistically distinct bands of sepsis probability, each with a progressively increased likelihood of sepsis. Additionally, observational data revealed that these bands correlated significantly with hospital care metrics and sepsis-related mortality. After 28 days, the sepsis-related mortality rate for Band 1 (low sepsis probability) was 0%, as compared to 2.5% in Band 2 and 4.4% in Band 3 (high sepsis probability). Moreover, among those eventually classified as septic requiring escalation of care from non-critical to critical care units during their hospital stay, none were in Band 1, in comparison with 58% and 42% in Bands 2 and 3, respectively.

The study also noted that equivalent amounts of resources from the Severe Sepsis and Septic Shock Management Bundle (SEP-1) were administered to all patients in the study, irrespective of risk band. This underlines IntelliSep's potential to assist healthcare providers in directing these limited clinical resources towards the patients in the most need. Data from the multi-center CV-SQuISH-ED clinical validation study also supports the U.S. Food and Drug Administration (FDA) 510(k) clearance of Cytovale’s IntelliSep test in December 2022, facilitating early detection of sepsis for approximately 30 million adults presenting with infection symptoms in U.S. EDs each year. Cytovale aims to make the IntelliSep test commercially available in the forthcoming quarter.

"Every minute counts when it comes to sepsis diagnosis, and EDs operate under major time and resource constraints that could impact patient outcomes,” said Dr. Hollis O’Neal, M.D., Medical Director of Research at Our Lady of the Lake Regional Medical Center, Critical Care Physician at LSU Health Sciences Center and National Principal Investigator and presenter for the CV-SQuISH-ED trial. “These results validate the efficacy and efficiency of IntelliSep as a diagnostic aid that may improve sepsis triage when incorporated into existing clinical protocols."

Related Links:
Cytovale 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.